In Brief: Gynecare
This article was originally published in The Gray Sheet
Gynecare: Submits premarket approval application to FDA for its ThermaChoice uterine balloon therapy system following completion of six-month follow-up from a 255-patient clinical trial of the device. The system is intended to treat menorrhagia, or excessive menstrual bleeding, a condition Gynecare says affects about 19% of menstruating women worldwide. Gynecare's clinical trial, conducted at 12 U.S. and two Canadian sites, compared use of ThermaChoice to electrosurgical ablation with a rollerball in women with blood flows of more than 80 cc each month. Based on a diary scoring system used in the study to assess blood loss, Gynecare says the two methods led to comparable reductions in blood loss. About 69.4% of ThermaChoice patients (n=131) were completed in less than 30 minutes versus 28.6% of rollerball patients (n=124)...
You may also be interested in...
Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.